Telomerase-Targeted Cancer Immunotherapy
AbstractTelomerase, an enzyme responsible for the synthesis of telomeres, is activated in many cancer cells and is involved in the maintenance of telomeres. The activity of telomerase allows cancer cells to replicate and proliferate in an uncontrolled manner, to infiltrate tissue, and to metastasize to distant organs. Studies to date have examined the mechanisms involved in the survival of cancer cells as targets for cancer therapeutics. These efforts led to the development of telomerase inhibitors as anticancer drugs, drugs targeting telomere DNA, viral vectors carrying a promoter for human telomerase reverse transcriptase (hTERT) genome, and immunotherapy targeting hTERT. Among these novel therapeutics, this review focuses on immunotherapy targeting hTERT and discusses the current evidence and future perspectives. View Full-Text
Share & Cite This Article
Mizukoshi, E.; Kaneko, S. Telomerase-Targeted Cancer Immunotherapy. Int. J. Mol. Sci. 2019, 20, 1823.
Mizukoshi E, Kaneko S. Telomerase-Targeted Cancer Immunotherapy. International Journal of Molecular Sciences. 2019; 20(8):1823.Chicago/Turabian Style
Mizukoshi, Eishiro; Kaneko, Shuichi. 2019. "Telomerase-Targeted Cancer Immunotherapy." Int. J. Mol. Sci. 20, no. 8: 1823.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.